PF-04979064 is primarily utilized in the field of medical research and drug development. It serves as a selective inhibitor of the enzyme phosphodiesterase 10A (PDE10A), which is highly expressed in the brain, particularly in the striatum. By inhibiting PDE10A, this compound helps modulate signaling pathways associated with dopamine and cyclic AMP (cAMP), making it a valuable tool for studying neurological and psychiatric disorders. Researchers use it to explore potential therapeutic applications for conditions such as schizophrenia, Huntington's disease, and Parkinson's disease. Its selectivity and potency make it a key compound in preclinical studies aimed at understanding the role of PDE10A in brain function and developing targeted treatments for these disorders.